How to choose Oligo dT resin for in vitro transcribed mRNA vaccine purification?

Oligo dT primarily captures Poly A-tailed mRNA and is not strong in selectivity for dsRNA, so don't expect to reduce dsRNA to very low levels with this step alone. It is recommended to add a tangential flow filtration or size exclusion/ultrafiltration step before Oligo dT to first remove unreacted NTPs and short fragments while reducing volume, which greatly lowers the loading burden on the resin. For dsRNA, hydrophobic interaction chromatography, ion-pair reversed-phase, or ion exchange can be used for polishing; some processes add enzymatic or precipitation steps before/after affinity. Note that lithium chloride precipitation has low recovery, which may be related to sample concentration, temperature, and centrifugation conditions; run a small-scale optimization before TFF. Don't directly attribute precipitation recovery issues to Oligo dT scale-up.

The volume of Oligo dT resin cannot be estimated solely based on a 1 L transcription system. You first need to measure the total amount and concentration of mRNA recovered after your IVT. Generally, before pilot-scale production, conduct a small-scale dynamic binding capacity experiment using your actual samples to measure the loading capacity in mg mRNA/mL resin, and it is recommended to leave a 20-30% safety margin. For example, after scale-up, if a batch has gram-level mRNA product, calculate the resin volume based on the binding capacity. Do not directly apply the amount after lithium chloride precipitation; it is best to use the IVT crude solution or partially purified samples to measure binding capacity, because impurities and viscosity can affect binding. A 1 L system may require anywhere from tens of milliliters to several hundred milliliters of resin, so obtain small-scale data first before deciding.

Flow rate is calculated based on bed height and retention time. For initial small-scale optimization, use a contact time of several minutes; do not directly copy the manufacturer's maximum flow rate. During scale-up, monitor bed pressure drop and whether the matrix deforms, especially since Oligo dT resins with agarose/polymer backbones differ in pressure tolerance. The number of regeneration cycles is not a fixed value; it depends on the cleanliness of your feed and cleaning conditions. It is recommended to record capacity, recovery, column pressure, and elution peak symmetry for each batch, and to run 5-10 consecutive cycles to observe decay. If capacity drops beyond the acceptable range, adjust the CIP protocol or shorten the regeneration interval. After regeneration, perform a column efficiency test and nucleic acid residue testing to prevent carryover from the previous batch contaminating the next batch.

Before scaling up the 1 L transcription system, ask suppliers for small-package resins to run capacity and flow rate experiments; do not directly purchase a pilot column. You can ask domestic distributors or original manufacturers: what the minimum specification is, whether they can provide reference data on Oligo dT ligand density and binding capacity, whether they have nuclease/endotoxin control reports, and whether they can provide pilot-scale cases for similar mRNA processes. Quotations and lead times vary widely; focus on confirming whether the resin is stocked or custom-made, and whether process scale-up support or trial columns are provided. You can compare 2-3 suppliers at the same time, first using the same batch of IVT samples for parallel testing on gravity columns or small chromatography columns, and then decide on pilot-scale procurement. Do not look only at the unit price; calculate the resin cost per gram of mRNA and the number of reusable cycles.